Nanoparticle Resveratrol Delivery for Triple-Negative Breast Cancer
Solution Overview
Problem
Current treatments for breast cancer, particularly triple-negative breast cancer, face challenges due to poor differentiation between healthy and malignant cells, leading to systemic toxicity and severe side effects, and the anticancer compound Resveratrol is limited by poor water solubility, short half-life, and chemical instability, which hinders its clinical effectiveness.
Innovation Solution
A nanoparticle composition using Poloxamer 407 as a surfactant, Vitamin E TPGS, and an anticancer compound like Resveratrol, which self-assembles into nanoparticles for targeted delivery, enhancing bioavailability and stability, and potentially incorporating fluorophore compounds for simultaneous diagnosis and therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat breast cancer, then malignant cells can be targeted, but healthy cells are also damaged causing systemic toxicity and severe side effects
Solution Approach 1:
The patent segments the chemotherapy delivery system into nanoparticle carriers that physically separate the drug from healthy tissues. The nanoparticles are designed to accumulate specifically in tumor tissue through the EPR effect, dividing the treatment impact from healthy cells while maintaining concentration at the target site.
Solution Approach 2:
The nanoparticle acts as an intermediary carrier between the chemotherapy drug and the tumor cells. This mediator enables targeted delivery by exploiting the unique physiological properties of tumor tissue (leaky vasculature and poor lymphatic drainage) to accumulate the drug specifically at the disease site rather than systemically.
2Reliability
If Resveratrol is administered to treat cancer, then anticancer activity can be achieved, but poor water solubility, short half-life, and chemical instability limit its effectiveness
Solution Approach 1:
The patent changes the physical and chemical parameters of Resveratrol by incorporating it into nanoparticle carriers. This transformation converts the poorly soluble small molecule into a stable nanoparticle formulation with improved water solubility, extended circulation half-life, and enhanced chemical stability through protection from degradation.
Solution Approach 2:
The nanoparticle provides a protective shell around the Resveratrol molecule, shielding it from chemical degradation in the biological environment. This flexible nanoscale encapsulation maintains the drug's stability during circulation and delivery while allowing controlled release at the target site.
3Reliability
If chemotherapy drugs are administered systemically, then cancer cells can be reached, but differentiation between healthy and malignant cells is poor resulting in severe side effects
Solution Approach 1:
The patent applies local quality by concentrating the chemotherapy drug specifically at the tumor site through nanoparticle accumulation. The high drug concentration is localized to the cancer tissue where it is needed, while healthy tissues receive minimal exposure, creating a spatial gradient of drug distribution that maximizes efficacy and minimizes side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle formulation improves the therapeutic efficacy of Resveratrol by increasing its bioavailability, stability, and specificity to cancer cells, reducing toxicity and side effects, while maintaining effectiveness against triple-negative breast cancer and other neoplastic diseases.
Implementation Method 1
A nanoparticle composition using Poloxamer 407 as a surfactant, Vitamin E TPGS, and an anticancer compound like Resveratrol, which self-assembles into nanoparticles for targeted delivery
Implementation Method 2
The nanoparticle formulation improves the therapeutic efficacy of Resveratrol by increasing its bioavailability, stability, and specificity to cancer cells
Data Source
AI summary
A nanoparticle for treatment of cancer is provided comprising a poloxamer surfactant, a Vitamin E TPGS and an anticancer compound.